|
Guest
|
Most recent articles on angiogenesis in prostate cancer:
Proliferation of immature tumor vessels is a novel marker of clinical
progression in prostate cancer.
Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA.
Cancer Res. 2009 Jun 1;69(11):4708-15.
Discovery of a novel proteasome inhibitor selective for cancer cells
over non-transformed cells.
Kazi A, Lawrence H, Guida WC, McLaughlin ML, Springett GM, Berndt N,
Yip RM, Sebti SM.
Cell Cycle. 2009 Jun 15;8(12):1940-51.
Molecular imaging of tumor blood vessels in prostate cancer.
Tilki D, Seitz M, Singer BB, Irmak S, Stief CG, Reich O, Ergün S.
Derya.Tilki at (no spam) med.uni-muenchen.de
Anticancer Res. 2009 May;29(5):1823-9.
Phase II study of sunitinib in men with advanced prostate cancer.
Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson
SZ, Spicer B, Gurski C, Kantoff PW, Smith MR.
dmichaelson1 at (no spam) partners.org
Ann Oncol. 2009 May;20(5):913-20.
Antitumor activity and mechanism of action of the cyclopenta[b]
benzofuran, silvestrol.
Cencic R, Carrier M, Galicia-Vázquez G, Bordeleau ME, Sukarieh R,
Bourdeau A, Brem B, Teodoro JG, Greger H, Tremblay ML, Porco JA Jr,
Pelletier J.
PLoS ONE. 2009;4(4):e5223.
Bone morphogenetic protein-10 suppresses the growth and aggressiveness
of prostate cancer cells through a Smad independent pathway.
Ye L, Kynaston H, Jiang WG.
yel at (no spam) cf.ac.uk
J Urol. 2009 Jun;181(6):2749-59.
Towards understanding the mode of action of the multifaceted cell
adhesion receptor CD146.
Ouhtit A, Gaur RL, Abd Elmageed ZY, Fernando A, Thouta R, Trappey AK,
Abdraboh ME, El-Sayyad HI, Rao P, Raj MG.
aouhti at (no spam) lsuhsc.edu
Biochim Biophys Acta. 2009 Apr;1795(2):130-6.
Stanniocalcin-1 acts in a negative feedback loop in the prosurvival
ERK1/2 signaling pathway during oxidative stress.
Nguyen A, Chang AC, Reddel RR.
Oncogene. 2009 May 7;28(1 :1982-92.
Angiotensin receptors in hormone-independent prostate cancer cell line
DU145: presence of two variants of angiotensin type 1 receptor.
Sidorkiewicz M, Rebas E, Szymajda M, Ławnicka H, Pawlikowski M,
Lachowicz A.
Med Sci Monit. 2009 Apr;15(4):BR106-10.
TMF/ARA160 downregulates proangiogenic genes and attenuates the
progression of PC3 xenografts.
Abrham G, Volpe M, Shpungin S, Nir U.
Int J Cancer. 2009 Jul 1;125(1):43-53.
Inactivation of uPA and its receptor uPAR by 3,3'-diindolylmethane
(DIM) leads to the inhibition of prostate cancer cell growth and
migration.
Ahmad A, Kong D, Sarkar SH, Wang Z, Banerjee S, Sarkar FH.
J Cell Biochem. 2009 Jun 1;107(3):516-27.
Novel antivascular efficacy of metronomic docetaxel therapy in
prostate cancer: hnRNP K as a player.
Benelli R, Monteghirfo S, Balbi C, Barboro P, Ferrari N.
Int J Cancer. 2009 Jun 15;124(12):2989-96.
Tumoristatic effects of endostatin in prostate cancer is dependent on
androgen receptor status.
Isayeva T, Moore LD, Chanda D, Chen D, Ponnazhagan S.
Prostate. 2009 Jul 1;69(10):1055-66.
Noninvasive imaging of the functional effects of anti-VEGF therapy on
tumor cell extravasation and regional blood volume in an experimental
brain metastasis model.
JuanYin J, Tracy K, Zhang L, Munasinghe J, Shapiro E, Koretsky A,
Kelly K.
Clin Exp Metastasis. 2009;26(5):403-14.
InTextoResearch, Baelen, Liège, Wallonie (Wallonia), Belgique
(Belgium) & Agence Wallonne d’Information Scientifique (AWIS) (Marc
Lacroix, scimedweb at (no spam) mail.com) |
|
|
